James S Scibetta - Net Worth and Insider Trading
James S Scibetta Net Worth
The estimated net worth of James S Scibetta is at least $849,981 dollars as of 2024-04-25. James S Scibetta is the President of Pacira BioSciences Inc and owns about 25,118 shares of Pacira BioSciences Inc (PCRX) stock worth over $650,556. James S Scibetta is the Director of Aquestive Therapeutics Inc and owns about 31,635 shares of Aquestive Therapeutics Inc (AQST) stock worth over $123,377. James S Scibetta is also the Director of Matinas BioPharma Holdings Inc and owns about 418,309 shares of Matinas BioPharma Holdings Inc (MTNB) stock worth over $76,049. Details can be seen in James S Scibetta's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that James S Scibetta has not made any transactions after 2019-08-21 and currently still holds the listed stock(s).
Transaction Summary of James S Scibetta
James S Scibetta Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, James S Scibetta owns 4 companies in total, including Matinas BioPharma Holdings Inc (MTNB) , Aquestive Therapeutics Inc (AQST) , and Pacira BioSciences Inc (PCRX) among others .
Click here to see the complete history of James S Scibetta’s form 4 insider trades.
Insider Ownership Summary of James S Scibetta
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MTNB | Matinas BioPharma Holdings Inc | 2017-09-07 | director |
| AQST | Aquestive Therapeutics Inc | 2019-08-21 | director |
| PCRX | Pacira BioSciences Inc | 2017-06-05 | Chief Financial Officer |
| NEPH | Nephros Inc | 2007-11-16 | director |
James S Scibetta Latest Holdings Summary
James S Scibetta currently owns a total of 3 stocks. Among these stocks, James S Scibetta owns 25,118 shares of Pacira BioSciences Inc (PCRX) as of June 5, 2017, with a value of $650,556 and a weighting of 76.54%. James S Scibetta owns 31,635 shares of Aquestive Therapeutics Inc (AQST) as of August 21, 2019, with a value of $123,377 and a weighting of 14.52%. James S Scibetta also owns 418,309 shares of Matinas BioPharma Holdings Inc (MTNB) as of September 7, 2017, with a value of $76,049 and a weighting of 8.95%.
Latest Holdings of James S Scibetta
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences Inc | 2017-06-05 | 25,118 | 25.90 | 650,556 |
| AQST | Aquestive Therapeutics Inc | 2019-08-21 | 31,635 | 3.90 | 123,377 |
| MTNB | Matinas BioPharma Holdings Inc | 2017-09-07 | 418,309 | 0.18 | 76,049 |
Holding Weightings of James S Scibetta
James S Scibetta Form 4 Trading Tracker
According to the SEC Form 4 filings, James S Scibetta has made a total of 0 transactions in Pacira BioSciences Inc (PCRX) over the past 5 years. The most-recent trade in Pacira BioSciences Inc is the sale of 1,966 shares on June 5, 2017, which brought James S Scibetta around $85,167.
According to the SEC Form 4 filings, James S Scibetta has made a total of 1 transactions in Aquestive Therapeutics Inc (AQST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Aquestive Therapeutics Inc is the acquisition of 22,971 shares on August 21, 2019, which cost James S Scibetta around $87,060.
According to the SEC Form 4 filings, James S Scibetta has made a total of 0 transactions in Matinas BioPharma Holdings Inc (MTNB) over the past 5 years. The most-recent trade in Matinas BioPharma Holdings Inc is the acquisition of 5,000 shares on September 7, 2017, which cost James S Scibetta around $6,450.
Insider Trading History of James S Scibetta
- 1
James S Scibetta Trading Performance
GuruFocus tracks the stock performance after each of James S Scibetta's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James S Scibetta is 25.57%. GuruFocus also compares James S Scibetta's trading performance to market benchmark return within the same time period. The performance of stocks bought by James S Scibetta within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how James S Scibetta's insider trading performs compared to the benchmark.
Performance of James S Scibetta
Average Return
12.49%
Outperforming Transactions
50%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -14.57 | 25.57 | -2.03 | 12.49 | 3.45 | 13.98 |
| Relative Return to S&P 500(%) | -15.82 | 21.46 | -6.68 | 1.92 | -9.75 | 1.5 |
James S Scibetta Ownership Network
Ownership Network List of James S Scibetta
Ownership Network Relation of James S Scibetta
James S Scibetta Owned Company Details
What does Matinas BioPharma Holdings Inc do?
Who are the key executives at Matinas BioPharma Holdings Inc?
James S Scibetta is the director of Matinas BioPharma Holdings Inc. Other key executives at Matinas BioPharma Holdings Inc include Chief Technology Officer Liu Hui , Chief Business Officer Thomas Hoover , and director & Chief Executive Officer Jerome D Jabbour .
Matinas BioPharma Holdings Inc (MTNB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Matinas BioPharma Holdings Inc (MTNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Matinas BioPharma Holdings Inc (MTNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Matinas BioPharma Holdings Inc (MTNB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Matinas BioPharma Holdings Inc Insider Transactions
James S Scibetta Mailing Address
Above is the net worth, insider trading, and ownership report for James S Scibetta. You might contact James S Scibetta via mailing address: C/o Bioenvision, Inc., 345 Park Avenue, 41st. Floor, New York Ny 10154.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
